Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main objective of this study is to assess the effect of mild, moderate and severe hepatic impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral administration of BI 10773 as a single dose.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

NCT02782624

Healthy

COMPLETED PHASE1

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

NCT01242176

Healthy

COMPLETED PHASE1

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

NCT01195675

Healthy

COMPLETED PHASE1

Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects

NCT02183376

Hepatic Insufficiency

COMPLETED PHASE1

Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food

NCT01189201

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Insufficiency Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 10773

50 mg single dose

Group Type EXPERIMENTAL

BI 10773

Intervention Type DRUG

2 tablets BI 10773 25 mg single dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 10773

2 tablets BI 10773 25 mg single dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.

Healthy subjects (group 1)

1. Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders as judged by the investigator.
2. Relevant gastrointestinal tract surgery.
3. Diseases of the central nervous system or psychiatric disorders or relevant neurological disorders.
4. History of relevant orthostatic hypotension, fainting spells or blackouts; systolic blood pressure \< 100 or \> 160 mm Hg, diastolic blood pressure \< 60 or \> 100 mm Hg, pulse rate \< 50 or \> 100 1/min.
5. Chronic or relevant acute infections.
6. History of allergy/hypersensitivity.
7. Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
8. Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation
9. Participation in another trial with an investigational drug within 2 months after a multiple dose study or within 1 month after a single dose study.
10. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day).
11. Inability to refrain from smoking when confined to the study site on trial days.
12. Alcohol abuse, drug abuse.
13. Veins unsuited for iv puncture on either arm.
14. Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
15. Excessive physical activities (within 48 hours prior to trial or during the trial).
16. Any laboratory value outside the reference range that is of clinical relevance.
17. Inability to comply with dietary regimen of study centre.
18. Subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Hepatically impaired subjects (group 2-4):
19. Decompensated gastrointestinal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
20. For patients with severe liver impairment (Child-Pugh C): Severe concurrent renal dysfunction (e.g., due to hepato-renal syndrome) and a creatinine clearance \<40mL/min.
21. Relevant gastrointestinal tract surgery.
22. Diseases of the central nervous system or psychiatric disorders or relevant neurological disorders.
23. Chronic or relevant acute infections.
24. History of allergy/hypersensitivity.
25. Intake of drugs with a long half-life (\>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
26. Use within 10 days prior to administration or during the trial of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation. Co-medication known to inhibit or induce P-glycoprotein (such as quinidine, cyclosporine, amiodarone) is not allowed. In dubious cases, a case by case decision will be made after consultation with the sponsor.
27. Participation in another trial with an investigational drug within 2 months after a multiple dose study or within 1 month after a single dose study.
28. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day).
29. Inability to refrain from smoking when confined to the study site on trial days.
30. Alcohol abuse, Drug abuse.
31. Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
32. Excessive physical activities (within 48 hours prior to trial or during the trial).
33. Clinically relevant laboratory abnormalities.
34. Inability to comply with dietary regimen of study centre.
35. Subjects not able to understand and comply with protocol requirements, instructions and protocol-stated restrictions

For female subjects of all groups:
36. Pregnancy
37. Positive pregnancy test
38. No adequate contraception during the study and until 2 months after study completion.
39. Lactation period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes